SomaticGNASMutation Causes Widespread and Diffuse Pituitary Disease in Acromegalic Patients with McCune-Albright Syndrome
SomaticGNASMutation Causes Widespread and Diffuse Pituitary Disease in Acromegalic Patients with McCune-Albright Syndrome
McCune-Albright syndrome (MAS) is caused by sporadic mutations of the GNAS. Patients exhibit features of acromegaly. In most patients, GH-secreting pituitary adenomas have been held responsible for this presentation. However, surgical adenomectomy rarely eliminates excess GH production.The aim of this study was to elucidate pituitary pathology in patients with MAS and to explain the basis of failure of adenomectomy to eliminate GH hypersecretion.We conducted a case series at the National Institutes of Health.Interventions included medical therapy and transsphenoidal surgery.We studied clinical and imaging features and the histology and molecular features of the pituitary of four acromegalic MAS patients.We identified widespread and diffuse pituitary gland disease. The primary pathological changes were characterized by hyperplastic and neoplastic change, associated with overrepresentation of somatotroph cells in structurally intact tissue areas. Genetic analysis of multiple microdissected samples of any type of histological area consistently revealed identical GNAS mutations in individual patients. The only patient with remission after surgery received complete hypophysectomy in addition to removal of multiple GH-secreting tumors.These findings indicate developmental effects of GNAS mutation on the entire anterior pituitary gland. The pituitary of individual cases contains a spectrum of changes with regions of normal appearing gland, hyperplasia, and areas of fully developed adenoma formation, as well as transitional stages between these entities. The primary change underlying acromegaly in MAS patients is somatotroph hyperplasia involving the entire pituitary gland, with or without development of somatotroph adenoma. Thus, successful clinical management, whether it is medical, surgical, or via irradiation, must target the entire pituitary, not just the adenomas evident on imaging.
- University of Freiburg Germany
- National Institute of Dental and Craniofacial Research United States
- National Institute for Dental and Craniofacial Research United States
- National Institute of Neurological Disorders and Stroke United States
- National Institutes of Health United States
Adenoma, Adult, Male, Endocrine Care, Human Growth Hormone, Pituitary Diseases, DNA Mutational Analysis, Mutation, Missense, insulin-like growth factor I, Fibrous Dysplasia, Polyostotic, Young Adult, Acromegaly, Journal Article, Chromogranins, GTP-Binding Protein alpha Subunits, Gs, acromegaly, young adult, Humans, Female, Growth Hormone-Secreting Pituitary Adenoma, Insulin-Like Growth Factor I
Adenoma, Adult, Male, Endocrine Care, Human Growth Hormone, Pituitary Diseases, DNA Mutational Analysis, Mutation, Missense, insulin-like growth factor I, Fibrous Dysplasia, Polyostotic, Young Adult, Acromegaly, Journal Article, Chromogranins, GTP-Binding Protein alpha Subunits, Gs, acromegaly, young adult, Humans, Female, Growth Hormone-Secreting Pituitary Adenoma, Insulin-Like Growth Factor I
14 Research products, page 1 of 2
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
chevron_left - 1
- 2
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).73 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
